GM130/GOLGA2 Antibody - BSA Free

Immunocytochemistry/ Immunofluorescence: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Immunocytochemistry/Immunofluorescence: GM130/GOLGA2 Antibody [NBP2-53420] - HeLa cells were fixed for 10 min using 10% formalin and then permeabilized for 5 min using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-GOLGA2 at 1:200 overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at 1:500. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at 1:1000 and detected with an anti-mouse DyLight 550 (Red) at 1:500. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Western Blot: GM130/GOLGA2 AntibodyBSA Free [NBP2-53420]

Western Blot: GM130/GOLGA2 Antibody [NBP2-53420] - Total protein from human HeLa and mouse Neuro2A cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 0.5 ug/mL anti-GOLGA2 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.

Immunohistochemistry-Paraffin: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Immunohistochemistry-Paraffin: GM130/GOLGA2 Antibody [NBP2-53420] - Analysis of a FFPE tissue section of mouse intesting using GM130/GOLGA2 antibody at 1:1500. The antibody generated staining in the the Golgi apparatus in the perinuclear region.

Immunocytochemistry/ Immunofluorescence: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Immunocytochemistry/Immunofluorescence: GM130/GOLGA2 Antibody [NBP2-53420] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with GM130/GOLGA2 Antibody conjugated to Biotin (NBP2-53420B) at 5 ug/ml for 1 hour at room temperature and detected with Streptavidin conjugated to DyLight 488. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Immunocytochemistry/ Immunofluorescence: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Immunocytochemistry/Immunofluorescence: GM130/GOLGA2 Antibody [NBP2-53420] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with GM130/GOLGA2 Antibody conjugated to FITC (NBP2-53420F) at 2 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Flow Cytometry: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Flow Cytometry: GM130/GOLGA2 Antibody [NBP2-53420] - An intracellular stain was performed on NIH3T3 cells with NBP2-53420 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).

Immunocytochemistry/ Immunofluorescence: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Immunocytochemistry/Immunofluorescence: GM130/GOLGA2 Antibody [NBP2-53420] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with GM130/GOLGA2 Antibody conjugated to FITC (NBP2-53420F) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Flow Cytometry: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Flow Cytometry: GM130/GOLGA2 Antibody [NBP2-53420] - An intracellular stain was performed on HeLa cells with NBP2-53420AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 min at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Flow Cytometry: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Flow Cytometry: GM130/GOLGA2 Antibody [NBP2-53420] - An intracellular stain was performed on MCF7 cells with GM130/GOLGA2 Antibody NBP2-53420AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Flow Cytometry: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420]

Flow Cytometry: GM130/GOLGA2 Antibody [NBP2-53420] - An intracellular stain was performed on HeLa cells with NBP2-53420 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).

Immunohistochemistry: Rabbit Polyclonal GM130/GOLGA2 Antibody [NBP2-53420] -

Immunohistochemistry: Rabbit Polyclonal GM130/GOLGA2 Antibody [NBP2-53420] - Staining of mouse C57BL/6 retina using GM130/GOLGA2 Antibody. GOLGA (red), BS-1 lectin (green), DAPI (blue). Primary antibody dilution: 1:200. Image from a verified customer review.

Western Blot: GM130/GOLGA2 Antibody - BSA Free [NBP2-53420] -

Extracellular vesicle secretion induced by Sorafenib and their miRNA content. (A) Particle size and concentration analysis of Large, Small, and Very Small EVs obtained at 6 and 24 h. (B) Expression of EV markers and cellular contaminants in Large, Small, and Very Small EVs and cell lysates obtained at 24 h after Sorafenib treatment. Total lane protein content was used as the loading control. (C) Representative images of cryo-EM of Small and Very Small EVs obtained at 6 and 24 h from the control and Sorafenib-treated cells. (D) Assessment of EV size (nm) in the cryo-EM images. (E) Number of EVs quantified in the cryo-EM images. (F) miRNA expression in the three fractions of EVs at 6 h. (G) miRNA expression in the three fractions of EVs at 24 h. Fold-change values were calculated between Sorafenib and the control treated samples. Results are expressed as the mean +/- SEM of six independent experiments. Ns, non-significant; * p ≤0.05, ** p ≤ 0.01, *** p ≤ 0.001, and **** p ≤ 0.0001 between the miRNA expression in the control and Sorafenib derived EVs. Multiple comparison test statistics are expressed with lower case a–i. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36078082), licensed under a CC-BY license. Not internally tested by Novus Biologicals.